Cardiovascular and Smooth Muscle Pharmacology aims to publish research related to the pharmacotherapy of cardiovascular disorders and those of other smooth muscle-rich organs, such as functional disorders of the heart, blood vessels, kidneys and urinary tract, as well as the central nervous system.
Indexed in: PubMed, PubMed Central, Scopus, Web of Science, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Index Copernicus
PMCID: all published articles receive a PMCID
Cardiovascular and Smooth Muscle Pharmacology welcomes submissions of the following tier 1 articles: Book Review, Editorial, General Commentary, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Protocols, Review, Specialty Grand Challenge and Technology Report.
All manuscripts must be submitted directly to the section Cardiovascular and Smooth Muscle Pharmacology, where they are peer reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Cardiovascular and Smooth Muscle Pharmacology will be subject to the Frontiers evaluation system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a prestigious Frontiers Focused Review - a tier 2 article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Pharmacology.